Biotricity to Present at LD Micro Invitational Investor Conference on June 7, 2016

REDWOOD CITY, CA / ACCESSWIRE / May 24, 2016 / Biotricity, Inc. (OTCQB: BTCY), a healthcare technology company dedicated to delivering innovative, medically relevant biometric remote monitoring solutions, has been invited to present at the sixth annual LD Micro Invitational, being held June 7-9, 2016 at the Luxe Sunset Bel Air.

Waqaas Al-Siddiq, Co-founder and CEO of Biotricity will present on Tuesday, June 7 at 11:00 a.m. Pacific time with 1×1 meetings held throughout the day. The conference will feature 195 companies in the small/micro-cap space and will be attended by investors, analysts and other influential members of the investment community.

Biotricity is focused on delivering ground-breaking, clinical-grade remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. The company’s flagship product, which is currently in development, is a mobile cardiac telemetry (MCT) solution that is designed to enable physicians to remotely monitor and diagnose cardiovascular disease (CVD) and coronary heart disease by detecting arrhythmias.

For more information or to request an invitation to the event, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

TWEET THIS: Med device provider @biotricity_inc invited to present at #LDMicroInvitational #wearables

View Biotricity’s profile here: http://www.ldmicro.com/profile/BTCY

Profiles powered by LD Micro – News Compliments of Accesswire

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

About Biotricity Inc.

Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Media Contacts

McCoin & Smith Communications Inc. for Biotricity
Chris McCoin, Chris@mccoinsmith.com, 508-429-5988
Richard Smith, rick@mccoinsmith.com, 978-433-3304

Investor Relations:

Michael Koehler
Liolios Group, Inc.
BTCY@liolios.com
949-574-3860

SOURCE: Biotricity, Inc. via LD Micro

ReleaseID: 440312